Id: | acc1155 |
Group: | 2sens |
Protein: | AKT |
Gene Symbol: | Akt1 |
Protein Id: | P31750 |
Protein Name: | AKT1_MOUSE |
PTM: | phosphorylation |
Site: | Ser473 |
Site Sequence: | ERRPHFPQFSYSASGTA---- |
Disease Category: | Cancer |
Disease: | Ovarian Cancer |
Disease Subtype: | |
Disease Cellline: | |
Disease Info: | |
Drug: | melatonin + cisplatin |
Drug Info: | Melatonin is a hormone that regulates sleep-wake cycles and is used to improve sleep quality or alleviate jet lag. Cisplatin is a platinum-based chemotherapeutic agent used to treat various cancers by interfering with DNA replication and inducing apoptosis in cancer cells. |
Effect: | modulate |
Effect Info: | "Melatonin inhibits the phosphorylation of members of the PTEN/AKT/FOXO3a pathway induced by cisplatin, thereby preventing cisplatin-induced primordial follicle loss during chemotherapy." |
Note: | drug comb |
Score: | 4.0 |
Pubmed(PMID): | 26882203 |
Sentence Index: | 26882203_8-9 |
Sentence: | "Additionally, we show that melatonin inhibited the cisplatin-induced inhibitory phosphorylation and nuclear export of FOXO3a, which is required in the nucleus to maintain dormancy of the primordial follicles. These findings demonstrate that melatonin attenuates cisplatin-induced follicle loss by preventing the phosphorylation of PTEN/AKT/FOXO3a pathway members; thus, melatonin is a potential therapeutic agent for ovarian protection and fertility preservation during chemotherapy in female cancer patients." |
Sequence & Structure:
MNDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQRESPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWATAIQTVADGLKRQEEETMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPTQRLGGGSEDAKEIMQHRFFANIVWQDVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 473 | D | Alzheimer's disease | Phosphorylation | 35834993 ;  36843923 |
S | 473 | D | Colonic inflammation | Phosphorylation | 36735734 |
S | 473 | D | Diabetes mellitus | Phosphorylation | 17130464 ;  16777975 ;  15033922 ;  15033922 ;  16777975 ;  17130464 ;  35739993 |
S | 473 | D | Turner syndrome | Phosphorylation | 33910978 |
S | 473 | U | Cardiomyopathy | Phosphorylation | 35358489 |
S | 473 | U | Diabetes mellitus | Phosphorylation | 35358489 |
S | 473 | U | Endometrial cancer/carcinoma | Phosphorylation | 16585156 |
S | 473 | U | Melanoma | Phosphorylation | 26565903 |
S | 473 | U | Non-small cell lung cancer | Phosphorylation | 35961388 |
S | 473 | U | Hepatocellular carcinoma | Phosphorylation | 33500384 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.